# Viking Therapeutics, Inc. (VKTX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Viking Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/VKTX/mda/fy2025/): filed 2026-02-11; accession 0001193125-26-046876 (https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/VKTX/mda/fy2024/): filed 2025-02-26; accession 0000950170-25-027824 (https://www.sec.gov/Archives/edgar/data/1607678/000095017025027824/vktx-20241231.htm)
- [FY 2023 MD&A](/company/VKTX/mda/fy2023/): filed 2024-02-07; accession 0000950170-24-012322 (https://www.sec.gov/Archives/edgar/data/1607678/000095017024012322/vktx-20231231.htm)
- [FY 2022 MD&A](/company/VKTX/mda/fy2022/): filed 2023-02-10; accession 0001564590-23-001685 (https://www.sec.gov/Archives/edgar/data/1607678/000156459023001685/vktx-10k_20221231.htm)
- [FY 2021 MD&A](/company/VKTX/mda/fy2021/): filed 2022-02-09; accession 0001564590-22-004429 (https://www.sec.gov/Archives/edgar/data/1607678/000156459022004429/vktx-10k_20211231.htm)

Back to /company/VKTX/